[CAS NO. 1258226-87-7] Ombitasvir

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1258226-87-7]

Catalog

HY-13997

Brand

MCE

CAS

1258226-87-7

DESCRIPTION [1258226-87-7]

Overview

MDL	MFCD28386270
Molecular Weight	894.11
Molecular Formula	C50H67N7O8
SMILES	CC(C)(C)C(C=C1)=CC=C1N2[C@H](C3=CC=C(NC([C@H]4N(C([C@@H](NC(OC)=O)C(C)C)=O)CCC4)=O)C=C3)CC[C@H]2C5=CC=C(NC([C@@H]6CCCN6C([C@@H](NC(OC)=O)C(C)C)=O)=O)C=C5

For research use only. We do not sell to patients.

6 Publications Citing Use of MCE

Summary

Ombitasvir is a potent inhibitor of the hepatitis C virus protein NS5A , with EC ₅₀ s of 0.82 to 19.3 pM against HCV genotypes 1 to 5, and 366 pM against genotype 6a.

IC50 & Target

EC50: 0.82 to 19.3 pM (HCV genotypes 1 to 5), 366 pM (HCV genotype 6a) ^[1]

In Vitro

Ombitasvir is active against the genotype 2a JFH-1 replicon, with an EC ₅₀ of 0.82 pM, and the EC ₅₀ s of ombitasvir are 42 pM and 68 pM against the L28 and F28 variants of this genotype 6a replicon, respectively ^[1] . In GT1a, variants M28V, L31V, and H58D confers 58- to 243-fold resistance to Ombitasvir. Single variants M28T, Q30R, and Y93C/S confers 800- to 8965-fold resistance, while Y93H/N confers >40000-fold resistance to Ombitasvir ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01609933	AbbVie (prior sponsor, Abbott)\|AbbVie	Chronic Hepatitis C	December 18, 2012	Phase 2
NCT01773070	AbbVie (prior sponsor, Abbott)\|AbbVie	Hepatitis C	June 2013	Phase 3
NCT03499639	Assiut University\|Sohag University\|South Valley University	End-stage Renal Disease\|HCV Coinfection	May 1, 2018	Phase 4
NCT02460133	Lisa Barrett\|PEI Provincial Correction Centre\|Nova Scotia Health Authority	Hepatitis C Virus	July 2015	Phase 4
NCT01458535	AbbVie (prior sponsor, Abbott)\|AbbVie	Hepatitis C Virus	September 2011	Phase 2
NCT01464827	AbbVie (prior sponsor, Abbott)\|AbbVie	Chronic Hepatitis C\|Hepatitis C (HCV)\|Hepatitis C Genotype 1	October 2011	Phase 2
NCT02333292	Valme University Hospital\|Hospital del SAS de Jerez\|Hospital General Universitario Elche\|Hospital La Línea de la Concepción\|Complexo Hospitalario Universitario de A Coruña\|Hospital de Figueres\|Hospital Universitario Puerto Real\|Hospital Universitario Virgen de la Victoria\|Hospital Universitario de Canarias\|Hospital General Universitario de Alicante\|Hospital Universitario Araba\|Hospital Royo Vilanova\|Hospital Universitario de Burgos\|Complejo Hospitalario Universitario de Huelva\|Hospital Universitario Reina Sofia de Cordoba\|Hospital Universitario Virgen Macarena\|Complejo Hospitalario Universitario de Vigo\|Clinica Universidad de Navarra, Universidad de Navarra\|Hospital Clinico Universitario San Cecilio\|Hospital Universitario La Fe\|Hospital General Universitario de Valencia\|Hospital Universitario Infanta Leonor\|Hospital Universitario de Gran Canaria\|Hospital General Universitario Santa Lucía\|Centro Penitenciario Alicante 1\|Hospital Regional Universitario Carlos Haya\|Hospital Virgen de la Luz\|Hospital General Universitario de Castellón\|Hospital Parc Taulí, Sabadell	Chronic Hepatitis C Infection	December 2014
NCT01314261	AbbVie (prior sponsor, Abbott)\|AbbVie	Chronic Hepatitis C\|Hepatitis C Virus (HCV) Infection	March 2011	Phase 2
NCT01685203	AbbVie (prior sponsor, Abbott)\|AbbVie	Hepatitis C, Chronic	August 2012	Phase 2
NCT01672983	AbbVie (prior sponsor, Abbott)\|AbbVie	Chronic Hepatitis C Infection	July 2012	Phase 2
NCT02486406	AbbVie	Chronic Hepatitis C Infection	October 28, 2015	Phase 2\|Phase 3
NCT01181427	Abbott	HCV Infection	August 2010	Phase 1
NCT01563536	AbbVie (prior sponsor, Abbott)\|AbbVie	Chronic Hepatitis C Infection	February 2012	Phase 2

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 33 mg/mL ( 36.91 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.1184 mL	5.5922 mL	11.1843 mL
5 mM	0.2237 mL	1.1184 mL	2.2369 mL
10 mM	0.1118 mL	0.5592 mL	1.1184 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (2.80 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (2.80 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

L-Prolinamide, 2,2′-[[(2S,5S)-1-[4-(1,1-dimethylethyl)phenyl]-2,5-pyrrolidinediyl]di-4,1-phenylene]bis[N-(methoxycarbonyl)-L-valyl-

2,2′-[[(2S,5S)-1-[4-(1,1-Dimethylethyl)phenyl]-2,5-pyrrolidinediyl]di-4,1-phenylene]bis[N-(methoxycarbonyl)-L-valyl-L-prolinamide]

ABT 267

Ombitasvir